Evaluation of ketamine as an adjuvant to scalp anesthesia for patients undergoing head surgery

Evaluation of ketamine as an adjuvant to scalp block for patients undergoing craniotomy - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091948

Enrollment

Registered

2025-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G893- Neoplasm related pain (acute) (chronic)

Interventions

Intervention1: Ketamine: Ketamine as an adjuvant to the solution prepared by mixing bupivacaine 0.25% and lignocaine adrenaline (1:1) at a maximum dose of 1mg/kg, in scalp block for patients posted fo

Eligibility

Inclusion criteria

Inclusion criteria: Patients posted for elective craniotomoy for supratentorial space occupying lesion, duration of surgery less than 4 hours, body mass index less than 24, ASA grade 1 or 2

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. ASA grade 3 or 4 3. Surgery for cerebral aneurysm or av malformation 4. Emergency surgery 5. Morbid obesity

Design outcomes

Primary

Measure	Time frame
Reduction in pain assessed by visual analog scaleTimepoint: Baseline, 2 hours,4 hours,8 hours,12 hours,24 hours (post operative)	—

Secondary

Measure	Time frame
Total intraoperative opioid consumption, intraoperative mean arterial pressure & heart rateTimepoint: Every 30 minutes till closure & at extubation	—

Countries

India

Contacts

Public ContactDr Amrita Roy

Institute of Neurosciences

royamrta@gmail.com8348641137

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026